Form 8-K - Current report:
SEC Accession No. 0001193125-24-237220
Filing Date
2024-10-15
Accepted
2024-10-15 08:00:01
Documents
16
Period of Report
2024-10-14
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d840698d8k.htm   iXBRL 8-K 26938
2 EX-99.1 d840698dex991.htm EX-99.1 8036
7 GRAPHIC g840698g1014234818389.jpg GRAPHIC 3997
  Complete submission text file 0001193125-24-237220.txt   203739

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vnda-20241014.xsd EX-101.SCH 4192
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vnda-20241014_def.xml EX-101.DEF 13769
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20241014_lab.xml EX-101.LAB 22890
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20241014_pre.xml EX-101.PRE 14737
19 EXTRACTED XBRL INSTANCE DOCUMENT d840698d8k_htm.xml XML 5720
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 241369324
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)